# Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Source: https://onco.cc/trials/nct04677816/  
OnCo record `nct04677816` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Wake Forest University Health Sciences, now recruiting.

## Summary

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients is a phase 2, interventional study registered as NCT04677816 by Wake Forest University Health Sciences, with a registry enrolment figure of 50 participants, started 2021-10-22 and due to reach its primary completion in 2026-12. Interventions recorded: Standard of Care Neoadjuvant Chemotherapy (NAC); Vitamin D3; Drug Diary. Conditions listed: Triple Negative Breast Cancer; Vitamin D Deficiency; Invasive Breast Cancer. Triple-negative eligibility wording from the registry: "* Known triple negative ER/PR/HER2 receptor status as defined by:". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04677816
- Phase: 2
- Setting: Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer
- Sponsor: Wake Forest University Health Sciences
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT04677816: https://clinicaltrials.gov/study/NCT04677816

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04677816.json